April 24, 2017 06:19 PM EDT

Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment

John Carroll

Editor & Founder

Marathon Pharmaceuticals has been quietly discussing plans to shutter its operations after kicking up a storm of controversy over an effort to market a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Marathon Phar­ma­ceu­ti­cals sig­nals it will wind down af­ter stir­ring a hor­net’s nest with $89,000 Duchenne treat­ment

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment